FOXP3 and melanoma: Bevacizumab in combination with temsirolimus was associated with reduced circulating FoxP3+ regulatory T‐cells compared with pretreatment samples.18 The addition of bevacizumab to carboplatin and paclitaxel chemotherapy appeared to improve survival and response rates, but this was not statistically significant.19 These studies were performed in patients with advanced melanoma but excluded brain metastases.